This Article Full Text Full Text (PDF) All Versions of this Article: 91/11/4277    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pilz, S. Articles by März, W. Search for Related Content PubMed PubMed Citation Articles by Pilz, S. Articles by März, W. Pubmed/NCBI databases Medline Plus Health Information Coronary Artery Disease Related Collections Cardiovascular Endocrinology Metabolism

Adiponectin and Mortality in Patients Undergoing Coronary Angiography

Clinical Institute of Medical and Chemical Laboratory Diagnostics (S.P., H.M., B.T.), Medical University Graz, A-8036 Graz, Austria; Ludwigshafen Risk and Cardiovascular Health Study nonprofit L.L.C. (B.W.,U.S.), D-79085 Freiburg, Germany; Division of Endocrinology (B.O.B.), Graduate School Molecular Diabetology and Endocrinology, Ulm University, D-89081 Ulm, Germany; Cardiology Group (B.R.W.), D-60594 Frankfurt Sachsenhausen, Germany; and Synlab Centre of Laboratory Diagnostics (W.M.), D-69031 Heidelberg, Germany

Address all correspondence and requests for reprints to: Professor Dr. Med. Winfried März, Synlab Centre of Laboratory Diagnostics, P.O. Box 10 47 80, D-69031 Heidelberg, Germany. E-mail: maerz{at}synlab.de.

Context: The adipokine adiponectin has been suggested to protect against coronary artery disease (CAD). However, studies addressing the association between adiponectin and mortality are sparse.

Objective: The objective of the study was to elucidate the relationship between adiponectin and mortality.

Design, Setting, and Participants: Adiponectin was determined in 2473 persons with and 673 persons without angiographic CAD. During a mean follow-up period of 5.45 yr, 427 persons with CAD and 55 persons without CAD died.

Main Outcome Measure: Hazard ratios for mortality according to adiponectin levels were measured.

Results: Adiponectin was positively related to female gender, age, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, homocysteine, and N-terminal pro-B-type natriuretic peptide. It was inversely related to glomerular filtration rate, body mass index, and triglycerides and was low in diabetes mellitus and CAD. An increase of 1 SD in adiponectin was associated with unadjusted and fully adjusted hazard ratios for death from any cause of 1.31 [95% confidence interval (CI) 1.20–1.42] and 1.22 (95% CI 1.12–1.34), and for death from cardiovascular causes of 1.32 (95% CI 1.19–1.45) and 1.23 (95% CI 1.11–1.37), respectively. In angiographic CAD, stable CAD, and unstable CAD, the predictive value of adiponectin was similar to that in the entire cohort, but it did not attain statistical significance in persons without angiographic CAD. Adiponectin was also positively related to the risk of death from noncardiovascular causes.

Conclusions: Despite the common view about adiponectin as a protective molecule in cardiovascular disease, high adiponectin independently predicts all-cause, cardiovascular, and noncardiovascular mortality in individuals with CAD.

This article has been cited by other articles:

				M. Cesari and G. P. Rossi Adiponectin and prognostic outcome in patients with coronary artery disease Eur. Heart J., October 2, 2008; 29(20): 2578 - 2579. [Full Text] [PDF]

				N. Sattar and S. M. Nelson Adiponectin, Diabetes, and Coronary Heart Disease in Older Persons: Unraveling the Paradox J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3299 - 3301. [Full Text] [PDF]

				J. R. Kizer, J. I. Barzilay, L. H. Kuller, and J. S. Gottdiener Adiponectin and Risk of Coronary Heart Disease in Older Men and Women J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3357 - 3364. [Abstract] [Full Text] [PDF]

				G. Maiolino, M. Cesari, D. Sticchi, M. Zanchetta, L. Pedon, K. Antezza, A. C. Pessina, and G. P. Rossi Plasma Adiponectin for Prediction of Cardiovascular Events and Mortality in High-Risk Patients J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3333 - 3340. [Abstract] [Full Text] [PDF]

				M. Rao, L. Li, H. Tighiouart, B. L. Jaber, B. J. G. Pereira, V. S. Balakrishnan, and the HEMO Study Group Plasma adiponectin levels and clinical outcomes among haemodialysis patients Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2619 - 2628. [Abstract] [Full Text] [PDF]

				M. Karmazyn, D. M. Purdham, V. Rajapurohitam, and A. Zeidan Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart Cardiovasc Res, July 15, 2008; 79(2): 279 - 286. [Abstract] [Full Text] [PDF]

				J. M. Dekker, T. Funahashi, G. Nijpels, S. Pilz, C. D. A. Stehouwer, M. B. Snijder, L. M. Bouter, Y. Matsuzawa, I. Shimomura, and R. J. Heine Prognostic Value of Adiponectin for Cardiovascular Disease and Mortality J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1489 - 1496. [Abstract] [Full Text] [PDF]

				R. Schnabel, C. M. Messow, E. Lubos, C. Espinola-Klein, H. J. Rupprecht, C. Bickel, C. Sinning, S. Tzikas, T. Keller, S. Genth-Zotz, et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study Eur. Heart J., March 1, 2008; 29(5): 649 - 657. [Abstract] [Full Text] [PDF]

				S. G. Wannamethee, P. H. Whincup, L. Lennon, and N. Sattar Circulating Adiponectin Levels and Mortality in Elderly Men With and Without Cardiovascular Disease and Heart Failure Arch Intern Med, July 23, 2007; 167(14): 1510 - 1517. [Abstract] [Full Text] [PDF]